• 提示：詳情請(qǐng)下載說明書。

• 產(chǎn)品描述： Telacebec (Q203, IAP6) 是一種新型抗結(jié)核藥物，通過抑制分枝桿菌細(xì)胞色素 bc1 復(fù)合物來靶向結(jié)核分枝桿菌（Mycobacterium tuberculosis） 細(xì)胞能量的產(chǎn)生。Telacebec 對(duì)結(jié)核分枝桿菌 H37Rv 具有活性，在培養(yǎng)基中的 MIC50 為 2.7 nM

• 靶點(diǎn)： Mycobacterium tuberculosis H37Rv:2.7 nM(MIC50);Antibacterial;?Antibiotic

• 體外研究：
  Telacebec (Q203) inhibits the growth of MDR and XDR M. tuberculosis clinical isolates in culture broth medium in the low nanomolar range.

• 體內(nèi)研究：
  Telacebec (Q203) is efficacious in a mouse model of tuberculosis at a dose less than 1 mg/kg body weight and displays pharmacokinetic and safety profiles compatible with once-daily dosing.

• 細(xì)胞實(shí)驗(yàn)： Cell lines: Raw 264.7 cells Concentrations: 0.1 nM-100 μM Incubation Time: -- Method: Telacebec (Q203) are incubated with macrophages previously. Raw 264.7 cells (American Type Culture Collection TIB-71) were infected with M. tuberculosis H37Rv-GFP at a multiplicity of infection of 2:1 and dispensed into plates. After 5 d of infection, macrophages were stained with Syto 60 for Image acquisition.

• 動(dòng)物實(shí)驗(yàn)： Animal Models: A high dose of M. tuberculosis H37Rv infected-acute tuberculosis BALB/c mouse model Dosages: 0.4, 2, 10 mg/kg Administration: Oral gavage

• 參考文獻(xiàn)：
  1. Veronique R de Jager, et al. Telacebec (Q203), a New Antituberculosis Agent. N Engl J Med. 2020 Mar 26;382(13):1280-1281. 2. Kevin Pethe, et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med. 2013 Sep;19(9):1157-60.

• 溶解性： Soluble  in  DMSO、Ethanol

• 保存條件： -20℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	1.795 ml	8.977 ml	17.953 ml
  5 mM	0.359 ml	1.795 ml	3.591 ml
  10 mM	0.18 ml	0.898 ml	1.795 ml
  50 mM	0.036 ml	0.18 ml	0.359 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

輸入產(chǎn)品批號(hào)：

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *